WebDoctor Encyclopedia

Pleural mesothelioma

Peritoneal mesothelioma

Peritoneal mesothelioma is a rare cancer of the lining of the abdomen. It often causes abdominal swelling from fluid and is treated with surgery plus heated chemotherapy (HIPEC) or with drug treatment.

Medically reviewed Last reviewed October 21, 2026

What is peritoneal mesothelioma?

Peritoneal mesothelioma is a rare cancer that starts in the peritoneum, the thin lining that covers the abdominal organs and the inside of the abdominal wall. The lining is made of mesothelial cells, which is where the name comes from.

The cancer usually spreads as many small nodules and sheets of tumour across the surface of the abdomen. It often causes a build-up of fluid (ascites), so swelling of the abdomen is a typical first sign. It usually stays within the abdomen, even when advanced.

It is the second most common type of mesothelioma after pleural mesothelioma, which affects the lining of the lungs. Its causes, typical patients and treatment differ in important ways. Exposure to asbestos plays a smaller role than in pleural disease, and many patients, particularly women, have never been exposed.

In the current WHO classification, the word “malignant” has been dropped: all mesotheliomas are regarded as cancers. Most peritoneal mesotheliomas are diffuse, meaning they spread across the peritoneum. Rare localised mesotheliomas form a single mass.

Outlook has improved considerably. For selected patients treated with cytoreductive surgery (CRS) and heated chemotherapy in the abdomen (HIPEC) at an expert centre, many are alive 5 years later and some are cured.

1. How common is it?

Peritoneal mesothelioma accounts for about 1 in 10 mesotheliomas. In the United States, there are about 1 new case per million people each year, which is roughly 300 cases a year.

Feature Details
Incidence About 1 per million people per year in Western countries
Share of mesotheliomas About 10% (pleural mesothelioma makes up most of the rest)
Age Usually 50-70; on average younger than people with pleural mesothelioma, and sometimes seen in young adults
Sex Men slightly more often, but the gap is much smaller than in pleural mesothelioma
Spread Mainly across the surfaces of the abdomen and pelvis; lymph node and distant spread are uncommon

2. Causes and risk factors

2.1 Asbestos

Asbestos is the main known cause. Asbestos fibres may reach the peritoneum after being breathed in or swallowed, and can cause long-term inflammation and damage to the DNA of mesothelial cells. The disease usually appears 20-50 years after exposure.

The link is weaker than for pleural mesothelioma. Peritoneal disease is most clearly linked with heavy exposure, particularly to amphibole types of asbestos such as crocidolite and amosite.

In many recent series, only a minority of patients report any asbestos exposure. In one MD Anderson series, only 4 of the 27 patients with a recorded history had been exposed.

Many women with peritoneal mesothelioma have no known exposure. In the Italian national mesothelioma register, women made up a much larger share of peritoneal than pleural cases, and their exposure was more often outside work. When exposure does occur in women, it is often from washing a worker’s clothes, from the home environment, or from industries not usually linked with asbestos.

2.2 Other risk factors

Risk factor Notes
Inherited gene changes Germline changes in BAP1 and, less often, other cancer genes (see below); more common in peritoneal disease and in people with little or no asbestos exposure
Erionite A fibrous mineral found in some volcanic rocks, best known from villages in central Turkey
Radiation Previous radiotherapy to the abdomen, for example for lymphoma or testicular cancer; also the old X-ray contrast agent Thorotrast
No known cause Common, particularly in women and younger patients

Peritoneal mesothelioma is not contagious and is not caused by diet or lifestyle.

2.3 BAP1 tumour predisposition syndrome

BAP1 is a tumour suppressor gene. It is switched off in the tumour cells of most peritoneal mesotheliomas. In a French study, more than 70% of tumours had at least one damaged copy of the gene, and about 57% had lost the BAP1 protein completely.

In a small number of families, a faulty copy of BAP1 is inherited. This causes BAP1 tumour predisposition syndrome (BAP1-TPDS), which is passed on in an autosomal dominant way: each child of a carrier has a 1 in 2 chance of inheriting it.

Feature Details
Linked cancers Mesothelioma (peritoneal and pleural), uveal (eye) melanoma, skin melanoma, kidney cancer (mainly clear cell), basal cell carcinoma
Skin sign Small, skin-coloured to reddish-brown bumps called BAP1-inactivated melanocytic tumours
Mesothelioma in carriers Appears at a younger age, often with little or no asbestos exposure, and is more often peritoneal
Outlook Often better than average: in one US study, carriers had a median survival of about 5 years
Frequency In a study of 198 people with mesothelioma, 12% carried a germline change in a cancer gene; BAP1 was the most common

Genetic counselling and germline testing are recommended for people with peritoneal mesothelioma, especially if they are young, had little asbestos exposure, have had another cancer, or have relatives with mesothelioma, eye melanoma, skin melanoma or kidney cancer. Carriers are usually offered regular skin and eye checks and kidney monitoring.

3. Types of peritoneal mesothelioma

3.1 Histological subtypes

Diffuse mesothelioma is divided into three subtypes according to how the cells look under the microscope. The subtype is one of the most important factors for treatment and outlook.

Subtype How common in the peritoneum Appearance Outlook
Epithelioid Most cases, about 75-90% Cuboidal cells forming tubules, papillae or solid sheets Best; the main group treated with CRS and HIPEC
Biphasic About 5-15% A mixture of epithelioid and sarcomatoid (spindle cell) areas Intermediate to poor, depending on the sarcomatoid share
Sarcomatoid Rare, a few per cent Spindle-shaped cells, like a sarcoma Poor; surgery is rarely helpful

Epithelioid tumours are more common in the peritoneum than in the pleura. Pathologists may also grade epithelioid tumours and note growth patterns that affect prognosis.

A rare type seen mainly in children and young adults carries an ALK gene rearrangement. It matters because it may respond to ALK-blocking drugs.

3.2 Tumours that must be told apart from mesothelioma

Two less aggressive mesothelial tumours, seen mainly in women, can look similar at surgery. They are managed very differently from diffuse mesothelioma, so an expert pathology review is essential.

Feature Well-differentiated papillary mesothelial tumour (WDPMT) Multicystic mesothelial tumour Diffuse mesothelioma
Former name Well-differentiated papillary mesothelioma Multicystic (benign cystic) mesothelioma; the WHO female genital volume calls these multilocular peritoneal inclusion cysts Malignant mesothelioma
Typical patient Women aged about 30-50; often found by chance during other surgery Women of reproductive age; pelvis most often Adults aged 50-70; both sexes
Appearance Small papillary nodules, usually a few millimetres to 2 cm Clusters of thin-walled, fluid-filled cysts Many nodules, thickened peritoneum and ascites
Microscope Branching papillae with a single layer of bland cells; no invasion Cysts lined by bland mesothelial cells; no invasion Invasion of fat, muscle or organs
BAP1 and MTAP Retained (normal) Retained (normal) BAP1 lost in more than half
Asbestos link Rare None known Present in a minority
Behaviour Usually benign; can recur, rarely progresses Benign, but can recur (in up to half in some series), especially after incomplete removal Cancer
Treatment Observation or removal Complete surgical removal; CRS with HIPEC in selected recurrent cases See section 8

The name well-differentiated papillary mesothelial tumour was introduced in the WHO 5th edition classification of thoracic tumours (2021) and is now also used for the peritoneum. The same edition described mesothelioma in situ, an early form that has not yet invaded. A tumour that looks like a WDPMT but has lost BAP1 is regarded as mesothelioma in situ or mesothelioma, so BAP1 staining is advised for every WDPMT.

4. How does it look?

4.1 On the body

Peritoneal mesothelioma cannot be seen from the outside in its early stages. As it grows, these changes may appear:

  • A swollen abdomen, which can become tight and large because of fluid.
  • A firm lump or a feeling of fullness in the abdomen.
  • A new hernia, often at the navel or groin, caused by raised pressure in the abdomen.
  • Weight loss in the face and limbs, even while the abdomen grows larger.

Doctors sometimes describe a “wet” type with a lot of ascites, a “dry” type with solid masses and pain, and a mixed type.

4.2 On scans

CT of the chest, abdomen and pelvis with contrast dye is the main test.

Finding What it looks like
Ascites Fluid around the bowel and organs
Thickened peritoneum Smooth or nodular thickening of the abdominal lining
Omental cake The fatty apron hanging from the stomach (omentum) becomes thick and solid with tumour
Mesentery The tissue that holds the bowel looks thickened and star-shaped, and bowel loops may be pulled together
Masses Larger solid tumours, mainly in the “dry” type

MRI helps to show small deposits, particularly on the bowel surface and in the pelvis. PET-CT shows active tumour and spread outside the abdomen. Scans tend to underestimate the true extent of disease, so a laparoscopy is often used to assess it directly.

4.3 During surgery and under the microscope

At surgery, the tumour usually appears as numerous white or grey nodules of different sizes on the peritoneum, the surface of the bowel, the diaphragm and the omentum. In advanced disease, they merge into sheets that can encase the bowel. The ascites is usually clear or straw-coloured.

Under the microscope, the pathologist confirms that the tumour is made of mesothelial cells and determines the subtype. This relies on immunohistochemistry, which uses stains for proteins found in mesothelial cells and in other cancers.

Stain type Examples Purpose
Mesothelial markers (positive) Calretinin, WT1, CK5/6, D2-40 (podoplanin), HEG1 Confirm that the tumour is mesothelial
Carcinoma markers (usually negative) Claudin-4, MOC-31, Ber-EP4, CEA, B72.3 Rule out cancers of the ovary, bowel, stomach or pancreas spread to the peritoneum
Markers of malignancy Loss of BAP1; loss of MTAP (a sign of CDKN2A deletion) Tell mesothelioma apart from reactive (benign) mesothelial cells and from WDPMT
Other tests Ki-67, ALK, PAX8, oestrogen receptor Proliferation rate, rare ALK-positive tumours, and separation from serous ovarian or peritoneal cancer

5. Symptoms

Symptoms usually develop slowly over months. They are often vague and similar to those of common digestive or gynaecological conditions, so diagnosis is often delayed.

Group Symptoms
Abdominal swelling Bloating, a tight or enlarged abdomen, clothes feeling tight around the waist; the most common symptom
Pain Dull ache or discomfort in the abdomen or pelvis
Digestive symptoms Feeling full quickly, loss of appetite, nausea, constipation or diarrhoea
General symptoms Weight loss, tiredness, fever and night sweats
Lump or hernia A lump in the abdomen or a new umbilical or groin hernia
Bowel obstruction Colicky pain, vomiting, swollen abdomen and inability to pass wind or stool; usually in advanced disease
Blood changes High platelet count, anaemia or blood clots in some patients

A few patients have no symptoms. Their tumour is found by chance during an operation or scan for another reason, often for a hernia or a gynaecological problem.

When to see a doctor

See a doctor if you have abdominal swelling, bloating, pain, a change in bowel habit or weight loss that lasts more than a few weeks. Mention any past contact with asbestos, even if it was brief or long ago.

Seek urgent care for severe abdominal pain, repeated vomiting, a hard swollen abdomen, or inability to pass wind or stool.

6. Diagnosis

Diagnosis needs a tissue sample, which should be reviewed by a pathologist experienced in mesothelial tumours. Fluid tests alone are often not enough.

Test Purpose
History and examination Symptoms, asbestos exposure, previous radiotherapy, personal and family history of cancer
CT of chest, abdomen and pelvis Extent of disease, ascites and spread outside the abdomen
MRI and PET-CT Small deposits and the extent of disease; used in selected patients
Fluid drainage (paracentesis) Relieves swelling; the fluid is checked for cancer cells, but results are often negative or unclear
Biopsy Core needle biopsy guided by CT or ultrasound, or laparoscopy with several biopsies; laparoscopy also shows the extent of disease and helps plan surgery
Blood tests Blood count, kidney and liver function; CA-125 and mesothelin may be raised and are mainly used for follow-up
Genetic tests Germline testing for BAP1 and other cancer genes; tumour testing in selected cases, for example for ALK

The main conditions to rule out are peritoneal spread from other cancers, especially ovarian, primary peritoneal, bowel, appendix and stomach cancer. Others are pseudomyxoma peritonei, WDPMT, peritoneal inclusion cysts, tuberculosis and reactive changes of the peritoneum.

7. Staging and the Peritoneal Cancer Index

7.1 Peritoneal Cancer Index (PCI)

The Peritoneal Cancer Index, devised by Jacquet and Sugarbaker, measures how much of the abdomen is involved. It is the most important measure for planning surgery.

Element Details
Regions The abdomen and pelvis are divided into 9 regions (0-8), and the small bowel into 4 further regions (9-12): 13 in total
Score per region 0 = no visible tumour; 1 = nodules up to 0.5 cm; 2 = up to 5 cm; 3 = larger than 5 cm or merging tumour
Total 0 to 39
How it is measured Estimated on CT or MRI; measured accurately at laparoscopy or open surgery

A lower PCI means a better chance of removing all visible disease. Involvement of the small bowel matters as much as the total score, because extensive bowel involvement can make complete surgery impossible.

7.2 Completeness of cytoreduction (CC score)

After surgery, the surgeon records how much tumour is left.

Score Remaining tumour
CC-0 No visible tumour
CC-1 Nodules smaller than 2.5 mm
CC-2 Nodules 2.5 mm to 2.5 cm
CC-3 Nodules larger than 2.5 cm or confluent disease

CC-0 and CC-1 are regarded as complete or near-complete cytoreduction and are linked with much better survival.

7.3 TNM staging

A staging system for peritoneal mesothelioma was proposed from an international registry of 294 patients treated with CRS and HIPEC. It is used by many specialist centres.

Stage Definition 5-year survival in the original registry
Stage I PCI 1-10, no lymph node or distant spread 87%
Stage II PCI 11-30, no lymph node or distant spread 53%
Stage III PCI over 30, or spread to lymph nodes or outside the abdomen 29%

These figures come from patients who were fit enough for major surgery, so they are better than for peritoneal mesothelioma as a whole.

8. Treatment

Treatment should be planned by a multidisciplinary team at a specialist peritoneal surface malignancy centre. The team includes surgeons, medical oncologists, pathologists, radiologists and palliative care specialists.

8.1 Guidelines

Because the disease is rare, there are no large randomised trials. Treatment is based on expert consensus:

  • PSOGI/EURACAN guidelines (2021): produced by the Peritoneal Surface Oncology Group International and the European rare cancer network. They recommend CRS with HIPEC as the preferred treatment for suitable patients with epithelioid disease, and advise against it for sarcomatoid tumours. A 2025 multisociety consensus using the GRADE method made a strong recommendation for CRS with HIPEC in carefully selected patients, despite the low certainty of the evidence.
  • Chicago Consensus (2020, updated 2025): a US pathway that sorts patients by histology, extent of disease and fitness. Low-risk patients are generally offered surgery first, intermediate-risk and suitable high-risk patients are considered for combined systemic treatment and surgery, and others receive systemic treatment. It recommends observation for benign tumours such as WDPMT and multicystic mesothelial tumours unless they cause symptoms or have worrying features.
  • NCCN guidelines (USA): separate guidance for peritoneal mesothelioma since 2023, covering surgery and systemic treatment.

All of these guidelines stress referral to expert centres and taking part in clinical trials.

8.2 Cytoreductive surgery and HIPEC

This is the only treatment that offers long-term control and, for some people, a cure.

Element Details
Who is suitable Epithelioid (sometimes selected biphasic) tumours; disease that can be completely removed (CC-0 or CC-1); no spread outside the abdomen; good general health; lymph node involvement and a high Ki-67 proliferation index are unfavourable features
Cytoreductive surgery Removal of all visible tumour: stripping of the diseased peritoneum (peritonectomy), removal of the omentum, and removal of affected organs such as parts of the bowel, the spleen, the gallbladder or the uterus and ovaries
HIPEC At the end of the operation, chemotherapy heated to about 41-43 degrees C is circulated through the abdomen for 60-90 minutes to treat remaining microscopic disease
HIPEC drugs Most often cisplatin, alone or with doxorubicin, or mitomycin C; regimens vary between centres
Duration The operation usually takes 6-12 hours, and the hospital stay is often 2-3 weeks
Risks Serious complications in about 30-50%, including leaks from bowel joins, infection, bleeding, blood clots and kidney problems; death within 90 days in about 2% at expert centres

In the largest international registry, 405 patients were treated with CRS and HIPEC. The median survival was 53 months, and 47% were alive at 5 years. Better survival was linked with epithelioid subtype, no lymph node spread, CC-0 or CC-1 surgery, and the use of HIPEC.

Some patients who cannot have complete surgery at first receive chemotherapy beforehand and are then reassessed. Some centres also give chemotherapy into the abdomen after surgery, either in the first days after the operation or as repeated treatments over a longer period.

8.3 Systemic treatment

Systemic treatment is used when surgery is not possible, when the disease comes back, and sometimes before or after surgery. Most evidence comes from pleural mesothelioma, because few trials have included peritoneal patients.

Treatment How it is given Evidence in peritoneal disease Common side effects
Platinum + pemetrexed Cisplatin or carboplatin with pemetrexed into a vein every 3 weeks, usually for 4-6 cycles; folic acid and vitamin B12 are given to reduce side effects The standard first-line chemotherapy. In expanded access programmes, about 1 in 4 people responded, and 57% of those given cisplatin-pemetrexed were alive at 1 year Tiredness, nausea, low blood counts, kidney and hearing effects (cisplatin)
Platinum + pemetrexed + bevacizumab As above, with bevacizumab, an antibody that blocks blood vessel growth (VEGF) Extrapolated from a pleural trial (MAPS); listed by NCCN High blood pressure, bleeding, protein in the urine, rarely bowel perforation
Nivolumab + ipilimumab Two immunotherapy drugs (PD-1 and CTLA-4 blockers) into a vein, for up to 2 years Approved for pleural disease after the CheckMate 743 trial, which did not include peritoneal patients; peritoneal data come from retrospective series (see below) Immune side effects affecting the skin, gut, liver, lungs and hormone glands
Atezolizumab + bevacizumab A PD-L1 blocker with bevacizumab into a vein every 3 weeks A phase 2 trial specifically in peritoneal mesothelioma after chemotherapy (see below); listed by NCCN for later treatment Immune side effects; high blood pressure, bleeding
Other drugs Gemcitabine, vinorelbine, or repeat pemetrexed after a long response Modest benefit in later lines Depend on the drug
ALK inhibitors Tablets such as crizotinib or alectinib Case reports in young patients with ALK-positive tumours Depend on the drug

8.4 Immunotherapy evidence in peritoneal disease

Peritoneal mesothelioma often contains many immune cells and expresses PD-L1, so it may respond to immunotherapy. The evidence is limited but encouraging.

Study Patients Results
Atezolizumab + bevacizumab, phase 2 trial (MD Anderson, 2021) 20 patients with advanced peritoneal mesothelioma that had progressed after platinum-pemetrexed 40% responded, with a median response duration of 12.8 months; 61% were free of progression and 85% were alive at 1 year. Responses occurred whatever the PD-L1 level
Immune checkpoint inhibitors, retrospective cohort (MD Anderson, 2021) 29 patients, 20 of them treated with nivolumab + ipilimumab 19% responded and 65% had disease control; median progression-free survival 5.5 months and median overall survival 19.1 months
Real-world French cohort (2025) 22 inoperable patients given immunotherapy, with or without anti-angiogenic drugs 30% of evaluable patients responded; median progression-free survival 10.2 months and median overall survival 16.8 months

In the US, nivolumab plus ipilimumab is listed as a first-line option for inoperable peritoneal mesothelioma, alongside platinum-pemetrexed. It is often preferred for biphasic and sarcomatoid tumours, which respond poorly to chemotherapy. Atezolizumab plus bevacizumab is listed as an option after chemotherapy for people who have not had immunotherapy. Approval and funding vary between countries, and immunotherapy for peritoneal mesothelioma is often given off-label.

8.5 Palliative care and symptom control

Palliative care should start early, alongside other treatment.

  • Ascites: repeated drainage, or a tunnelled abdominal catheter that allows fluid to be drained at home.
  • Bowel obstruction: a drip and a stomach tube, medicines that reduce vomiting and bowel secretions, and sometimes surgery or a stent.
  • Pain: regular pain relief, including opioids when needed, and nerve blocks in selected cases.
  • Nutrition: advice from a dietitian, small frequent meals, supplements and, rarely, feeding into a vein.
  • Blood clots: awareness of leg swelling and breathlessness, and anticoagulant treatment when needed.

9. Prognosis

Outlook varies widely and depends mainly on the subtype, the extent of disease and whether complete surgery is possible.

Group Typical survival
All patients (US cancer registry, 2000-2018) Median about 12 months; about 17 months for epithelioid and about 2 months for sarcomatoid tumours
CRS with HIPEC, international registry Median 53 months; 47% alive at 5 years
CRS with HIPEC, France 2012-2021 (924 patients) 5-year survival 85% for those suitable for surgery from the start and 55% for borderline cases
Not suitable for surgery (same French data) 13% alive at 5 years
Chemotherapy or immunotherapy alone Median survival usually about 1-2 years
BAP1 germline carriers Often longer than average; median about 5 years in one series

Survival has improved in recent years, partly because more patients have surgery at specialist centres. Women and people with epithelioid tumours, low PCI, no lymph node spread and complete cytoreduction do best. Survival figures from surgical centres apply to fit, carefully selected patients and are higher than for peritoneal mesothelioma as a whole.

10. Follow-up and living with peritoneal mesothelioma

10.1 Follow-up

After CRS and HIPEC, follow-up usually includes a CT scan and CA-125 or other markers every 3-6 months for the first few years, then less often, for many years. Recurrence is usually inside the abdomen. Some patients with recurrence can have a second operation.

10.2 Everyday life

  • Recovery from CRS and HIPEC takes several months. Tiredness, a reduced appetite and changes in bowel habit are common at first.
  • Some people have a temporary or permanent stoma and receive help from a stoma nurse.
  • Report new swelling, pain, vomiting or weight loss to your team promptly.
  • Ask about genetic testing, especially if you are young or have relatives with related cancers.
  • In many countries, people with mesothelioma may be entitled to compensation or benefits, particularly if asbestos exposure is suspected. A specialist nurse or patient organisation can advise.
  • Patient organisations such as Mesothelioma UK offer information, specialist nurses and support groups.

Resources

  1. Boffetta, P. (2007) ‘Epidemiology of peritoneal mesothelioma: a review’, Annals of Oncology, 18(6), pp. 985-990.
  2. Calthorpe, L. et al. (2023) ‘Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States’, Cancers, 15(1), p. 229.
  3. Marinaccio, A. et al. (2018) ‘The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure’, Occupational and Environmental Medicine, 75(4), pp. 254-262.
  4. Testa, J.R. et al. (2011) ‘Germline BAP1 mutations predispose to malignant mesothelioma’, Nature Genetics, 43(10), pp. 1022-1025.
  5. Carbone, M. et al. (2020) ‘Biological mechanisms and clinical significance of BAP1 mutations in human cancer’, Cancer Discovery, 10(8), pp. 1103-1120.
  6. Panou, V. et al. (2018) ‘Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma’, Journal of Clinical Oncology, 36(28), pp. 2863-2871.
  7. Pastorino, S. et al. (2018) ‘A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations’, Journal of Clinical Oncology, 36(35), pp. 3485-3494.
  8. Leblay, N. et al. (2017) ‘BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas’, Journal of Thoracic Oncology, 12(4), pp. 724-733.
  9. Sauter, J.L. et al. (2022) ‘The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification’, Journal of Thoracic Oncology, 17(5), pp. 608-622.
  10. Churg, A. (2024) ‘New developments in mesothelial pathology’, Histopathology, 84(1), pp. 136-152.
  11. Hassan, A. et al. (2024) ‘The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature’, Pathology, 56(5), pp. 662-670.
  12. Jacquet, P. and Sugarbaker, P.H. (1996) ‘Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis’, Cancer Treatment and Research, 82, pp. 359-374.
  13. Yan, T.D. et al. (2009) ‘Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience’, Journal of Clinical Oncology, 27(36), pp. 6237-6242.
  14. Yan, T.D. et al. (2011) ‘A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database’, Cancer, 117(9), pp. 1855-1863.
  15. Kusamura, S. et al. (2021) ‘Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up’, European Journal of Surgical Oncology, 47(1), pp. 36-59.
  16. Kusamura, S. et al. (2025) ‘Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of diffuse malignant peritoneal mesothelioma: a GRADE approach for evidence evaluation and recommendation’, Journal of Surgical Oncology, 131(5), pp. 810-815.
  17. Chicago Consensus Working Group (2020) ‘The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma’, Annals of Surgical Oncology, 27(6), pp. 1774-1779.
  18. Brown, L.M. et al. (2025) ‘Consensus guideline for the management of peritoneal mesothelioma’, Cancer, 131(13), e35868.
  19. Noiret, B. et al. (2026) ‘Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients’, European Journal of Surgical Oncology, 52(4), 111492.
  20. Janne, P.A. et al. (2005) ‘Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program’, Clinical Lung Cancer, 7(1), pp. 40-46.
  21. Carteni, G. et al. (2009) ‘Malignant peritoneal mesothelioma: results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent’, Lung Cancer, 64(2), pp. 211-218.
  22. Baas, P. et al. (2021) ‘First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial’, The Lancet, 397(10272), pp. 375-386.
  23. Raghav, K. et al. (2021) ‘Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma’, Cancer Discovery, 11(11), pp. 2738-2747.
  24. Raghav, K. et al. (2021) ‘Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma’, JAMA Network Open, 4(8), e2119934.
  25. Smolenschi, C. et al. (2025) ‘Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: a French experience’, European Journal of Cancer, 231, 116066.
  26. Ettinger, D.S. et al. (2023) ‘Mesothelioma: peritoneal, version 2.2023, NCCN Clinical Practice Guidelines in Oncology’, Journal of the National Comprehensive Cancer Network, 21(9), pp. 961-979.
  27. Tanvetyanon, T. and Simon, G.R. (2024) ‘Systemic therapy options for peritoneal mesothelioma’, Journal of the National Comprehensive Cancer Network, 22(8), e247031.
  28. National Cancer Institute (2026) Malignant Mesothelioma Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq (Accessed: October 2026).
  29. Mesothelioma UK (2026) Mesothelioma UK. Available at: https://www.mesothelioma.uk.com/ (Accessed: October 2026).

Prepared by the editorial team, October 2026.